Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 14/20 | 0.59 |
| ▸ | KDM5C | P41229 | 8/20 | 0.59 |
| ▸ | KDM5A | P29375 | 7/20 | 0.59 |
| ▸ | KDM4A | O75164 | 2/20 | 0.59 |
| ▸ | KDM6B | O15054 | 1/20 | 0.59 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.58 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15994214 | 0.92 | KDM5B (0.72) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL15994219 | 0.91 | KDM5B (0.61) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL19676485 | 0.88 | KDM5B (0.55) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL16303341 | 0.88 | KDM5B (0.53) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL18880295 | 0.84 | KDM5B (0.51) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL16293695 | 0.82 | KDM5B (0.46) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL17364568 | 0.81 | KDM5B (0.59) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL15994395 | 0.81 | KDM5B (0.51) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL18880361 | 0.81 | KDM5B (0.51) | KDM5BKDM5CKDM5AKDM4AKDM6B | |
| SCHEMBL15994396 | 0.81 | KDM5B (0.51) | KDM5BKDM5CKDM5AKDM4AKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | KDM5B 27/4885KDM5C 16/4885KDM5A 21/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | KDM5B 27/4885KDM5C 16/4885KDM5A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.